Preventing adaptive drug resistance through Mediator kinase inhibition
通过抑制介体激酶来预防适应性耐药性
基本信息
- 批准号:10668528
- 负责人:
- 金额:$ 59.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAntineoplastic AgentsBreast Cancer cell lineBreast CarcinomaCell LineCellsDerivation procedureDevelopmentDrug TargetingDrug resistanceERBB2 geneEpitheliumExposure toGene ExpressionGenetic TranscriptionGenomicsGrowthHeterogeneityHumanHuman Cell LineImmuneImmune systemImmunocompetentImmunodeficient MouseImmunologic Deficiency SyndromesIn VitroMalignant Epithelial CellMediatorMesenchymalMicroRNAsMouse Mammary Tumor VirusMusMutagenesisNeoplasm MetastasisPaclitaxelPathway interactionsPatient-derived xenograft models of breast cancerPatientsPharmaceutical PreparationsPharmacotherapyPhenotypePhosphorylationPhosphotransferasesPopulationPreventionProcessPropertyProtein IsoformsProtein KinaseRemission InductionResistanceResistance developmentRoleSignal TransductionSignal Transduction PathwayStromal CellsTestingTreatment outcomeTumor PromotionXenograft procedureacquired drug resistancecancer drug resistancecancer stem cellcancer therapyclinical developmentclinically relevantexome sequencinggene inductiongenetically modified cellsin vivoinhibitorinhibitor therapykinase inhibitorlapatinibmalignant breast neoplasmmiRNA expression profilingmouse modelmutantneoplastic cellnon-geneticnovelnovel drug classnovel therapeuticspatient derived xenograft modelpharmacologicpre-clinicalpreventprogramsprototypesingle-cell RNA sequencingtherapy developmenttherapy resistanttranscription factortranscriptional reprogrammingtranscriptome sequencingtranscriptomicstumortumor growthtumor initiationtumor progressiontumor xenograft
项目摘要
Cancer drug resistance is driven in part by the plasticity of tumor cells that allows for therapy-induced adaptation
of their transcriptional program. This adaptive drug resistance is associated with the acquisition of various
phenotypic changes that promote tumor growth, metastasis and resistance to other therapies. Experimental
drugs targeting CDK8/19 Mediator kinase that regulates transcriptional reprogramming were found to suppress
the development of resistance to different classes of targeted and conventional anticancer agents. We
hypothesize that the emergence of adaptive drug resistance in vitro and in vivo, with concurrent acquisition of
tumor-promoting phenotypes, can be prevented by inhibiting Mediator kinase. We will test this hypothesis in
HER2-positive breast cancers by analyzing the effects of Mediator kinase inhibition on the emergence of
resistance to a HER2-targeting drug (lapatinib) and a conventional drug (paclitaxel). We will pursue the following
Specific Aims. (1) The effect of Mediator kinase deficiency on the development of adaptive drug resistance in
vitro will be analyzed by generating derivatives of HER2-positive human breast cancer cell lines that will express
wild-type or kinase-dead Mediator kinase and by analyzing the effects of Mediator kinase mutagenesis or
treatment with selective CDK8/19 inhibitors on the emergence of adaptive resistance to lapatinib or paclitaxel.
Comprehensive phenotypic, genomic and transcriptomic analyses will be used to evaluate the effect of drug
adaptation and Mediator kinase inhibition on the acquisition of tumor-promoting phenotypes and to identify signal
transduction pathways, inhibitors of which could be combined with CDK8/19 inhibitors to enhance the prevention
of resistance. (2) HER2-positive human cell lines with different Mediator kinase status and a panel of HER2-
positive breast cancer patient-derived xenografts (PDX) will be selected for lapatinib and paclitaxel resistance in
vivo, to compare the resistance-preventing effects of Mediator kinase deficiency in tumor cells alone and with
the effects of its pharmacological inhibition in both tumor and stromal cells. Transcriptomic and phenotypic
analysis will be used to delineate the effects of drug selection and Mediator kinase inhibition on gene expression
in tumor and stromal cells. Whole exome sequencing of PDX tumors will reveal if Mediator kinase inhibition
prevents the emergence of new drug-resistant tumor lineages or suppresses the growth of drug-resistant cells
that may pre-exist in heterogeneous PDXs. (3) The effects of Mediator kinase on the emergence of drug
resistance will also be investigated in a murine Her2/Neu-driven mouse mammary carcinoma cells adapted for
syngeneic growth, both in vitro (as in Aim 1) and in vivo using both immunocompetent and immunodeficient
hosts. This analysis will elucidate the effect of the host immune system on drug adaptation and the role of
Mediator kinase in this effect. The proposed program will delineate the roles of Mediator kinase in tumor
adaptation to treatment, in vitro and in vivo, and will indicate whether Mediator kinase-inhibiting drugs may be
able to extend the duration of remission induced by cancer therapy.
癌症耐药性部分是由肿瘤细胞的可塑性驱动的,这种可塑性允许治疗诱导的适应
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eugenia V Broude其他文献
Eugenia V Broude的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eugenia V Broude', 18)}}的其他基金
Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition
通过抑制介体激酶来预防体内对 PI3K/AKT/mTOR 抑制剂的耐药性
- 批准号:
10602700 - 财政年份:2022
- 资助金额:
$ 59.69万 - 项目类别:
Preventing adaptive drug resistance through Mediator kinase inhibition
通过抑制介体激酶来预防适应性耐药性
- 批准号:
10518499 - 财政年份:2022
- 资助金额:
$ 59.69万 - 项目类别:
Potentiating targeted drugs in breast cancer via transcription-regulating kinases
通过转录调节激酶增强乳腺癌靶向药物
- 批准号:
9794385 - 财政年份:2019
- 资助金额:
$ 59.69万 - 项目类别:
Selective Targeting of Phosphodiesterase 11A Transcription and Catalytic Activit
磷酸二酯酶 11A 转录和催化活性的选择性靶向
- 批准号:
9061733 - 财政年份:
- 资助金额:
$ 59.69万 - 项目类别:
Selective Targeting of Phosphodiesterase 11A Transcription and Catalytic Activit
磷酸二酯酶 11A 转录和催化活性的选择性靶向
- 批准号:
9274311 - 财政年份:
- 资助金额:
$ 59.69万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 59.69万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 59.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 59.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 59.69万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 59.69万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 59.69万 - 项目类别: